Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Imaging for clinical trials

iBiopsy® Enhancing Imaging Diagnostic Accuracy

Using novel non-invasive AI-powered digital biomarkers, we are transforming the imaging diagnostic world by developing the most accurate cutting-edge proprietary AI-powered software across multiple imaging modalities.
Our focus is to achieve accurate early diagnosis and treatment to improve patient lives by helping radiologists and clinicians in their diagnostic workflow in oncology and metabolic diseases.

iBiopsy

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

Median's latest news

Fredrik Brag, CEO and founder of Median, provides additional insight on our two latest company’s announcements: the iBiopsy® Lung Cancer Screening CADx outstanding performance and the recent confirmation of Median as a preferred vendor by one of the Top 3 pharma companies in the world (interview in French).


Watch video

Latest press releases

21 October 2021

Median Technologies reports on its 2021 half-year results and its Q3 2021 business activity indicators 

Business continues to grow at a sustained pace in the first half of 2021 – Two highly impactful announcements for iBiopsy® and iCRO business units during Q3, 2021 -Third quarter revenue of €5.3m, up by 51% on the third quarter of 2020 – Cash and cash equivalents of €42.6m as of September 30th, 2021

16 September 2021

Median Technologies has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world, and selected to implement their clinical trial imaging strategy on some key oncology indications

This is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company. The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years. This partnership will contribute to sustain Median’s future bookings and revenues growth.

14 September 2021

Median Technologies changes the publication date of its H1 2021 results

Median Technologies (ALMDT: PA) will announce its H1 2021 results as well as its Q3 2021 business performance indicators on October 21, 2021 after trading close instead of October 14, 2021 after trading close.

6 September 2021

Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort

Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx[1] to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort. Results show cutting-edge performance of 95.2% sensitivity and 95.7% specificity for lung nodule characterization that could significantly impact lung cancer screening programs adoption. The large-scale study is based on a cohort of 1,696 patients with a total of 15,608 lung nodules. Further results on a fully automated end-to-end lung cancer screening CADe/CADx including nodule detection and characterizationre expected in Q4, 2021.

29 July 2021

Median Technologies appoints Jean-Christophe Montigny as Chief Financial Officer and member of the Executive Committee

Median Technologies (ALMDT) today announces the appointment of Jean-Christophe Montigny as Chief Financial Officer. He will be a member of Median’s executive committee.

1/5

Our Summer Corporate Newsletter

We are pleased to share with you our Summer Corporate Newsletter, presenting our most recent announcements and what we did during the second quarter of 2021 and in early Q3. Click below to read the Newsletter!

Webinars

JULY 1, 2021

Optimizing Clinical Trial Design for Central Reads

Optimizing clinical trial design can have a huge influence on oncology studies that are dependent on imaging for evaluations. Depending on the study design, several alternatives can be considered for improving imaging results that support these endpoints: different assessment paradigms, incorporation of clinical data in addition to radiographic reads, etc… During this presentation, we review the relevance of each option for different study designs. Watch the webinar video now!

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Pioneer of a new imaging diagnostic world

Our team of data scientists, AI engineers & clinicians is focused on developing the most accurate AI-powered software. iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis and treatment, avoiding unnecessary invasive tests.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median